OmniStar Financial Group Inc. Sells 4,444 Shares of Johnson & Johnson (NYSE:JNJ)

OmniStar Financial Group Inc. lowered its position in Johnson & Johnson (NYSE:JNJ) by 48.5% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 4,719 shares of the company’s stock after selling 4,444 shares during the quarter. OmniStar Financial Group Inc.’s holdings in Johnson & Johnson were worth $769,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. KMG Fiduciary Partners LLC boosted its stake in Johnson & Johnson by 54.4% in the 1st quarter. KMG Fiduciary Partners LLC now owns 32,778 shares of the company’s stock worth $5,185,000 after purchasing an additional 11,548 shares during the period. American National Bank lifted its stake in Johnson & Johnson by 5.3% in the 1st quarter. American National Bank now owns 73,938 shares of the company’s stock worth $11,696,000 after purchasing an additional 3,743 shares in the last quarter. M. Kraus & Co boosted its holdings in Johnson & Johnson by 0.5% in the 1st quarter. M. Kraus & Co now owns 53,914 shares of the company’s stock valued at $8,529,000 after purchasing an additional 253 shares during the period. Park Avenue Securities LLC grew its position in shares of Johnson & Johnson by 3.1% during the 1st quarter. Park Avenue Securities LLC now owns 48,942 shares of the company’s stock valued at $7,742,000 after purchasing an additional 1,476 shares in the last quarter. Finally, Nexus Investment Management ULC boosted its stake in Johnson & Johnson by 9.1% during the first quarter. Nexus Investment Management ULC now owns 8,376 shares of the company’s stock valued at $1,325,000 after buying an additional 700 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Trading Up 0.4 %

NYSE JNJ opened at $165.13 on Friday. The stock has a 50-day moving average of $162.98 and a 200-day moving average of $154.71. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $168.85. The firm has a market cap of $397.41 billion, a PE ratio of 10.29, a price-to-earnings-growth ratio of 2.65 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The firm had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. During the same quarter in the prior year, the firm posted $2.66 earnings per share. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. As a group, sell-side analysts forecast that Johnson & Johnson will post 10 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.00%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s payout ratio is 30.92%.

Insider Activity

In related news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on the company. TD Cowen reduced their target price on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research report on Thursday, July 18th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday. Daiwa America cut shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Morgan Stanley raised their price objective on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research report on Wednesday. Finally, Daiwa Capital Markets lowered shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Six research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $175.93.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.